Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO)

BOYNTON BEACH, FLORIDA, USA, July 25, 2013 /EINPresswire.com/ -- Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA

Pressure Biosciences (OTCQB: PBIO), a notable life sciences company that develops pressure-based technologies used for analyzing cells and molecules in various fields of study, continues its upward trending well into 2013 with plenty of bright accomplishments. Its patented “pressure cycling technology,“ or PCT, remains a leading resource for controlling the action of molecular cell and tissue samples.

Since last year, the company has seen surging growth, showing increased revenue while also posting decreased operating losses. Following a series of milestones in the last few months alone, it almost appears as if PBIO, currently selling at .27/share with a market cap of 3.09million, can do no wrong. A shortlist of PBIO’s recent successes:

June 14th PBIO closed the final tranche in its Series J Private Placement of Convertible Preferred Stock and Warrants, exceeding its initial goal of $2 million by reaching a combined total of $2,034,800 in all three of its Series J Private Placement closings. 5,087 units were sold in this third and final closing, at a rate of $400 per unit.

June 7th Concurrent to the final tranche closing, the company closed a $500K, one-year convertible debenture with an institutional investor. CEO Richard T. Schumacher referred to this and the tranche closing as developments in a “clear and attainable path to financial strength.”

June 4th It was announced that Pressure Biosciences reached required “proof-of-principle” objectives in their development of high throughput (“HT”) technology designed to aid their proprietary “PCT” pressure cycling technology in integrating with HT systems already installed in many modern laboratories. Rather than limit itself to the small number of laboratories with resources sufficient to house the manual PCT platform, PBIO’s implementation of the automated HT format already in such common use, will introduce the company to a much wider market.

May 29th PBIO entered into an agreement with Merriman Capital, Inc, which states that Merriman will advise several initiatives intended to increase PBIO’s shareholder value, and ultimately, overall market holdings. Among Merriman’s duties will be the development of strategies to increase stock liquidity and the assessment of potential gains in pursuing other venues such as NASDAQ and NYSE.

May 21st The release of PBIO’s First Quarter 2013 financial results created a surge of momentum for the company with the report that, compared to Q1 2012 totals, overall revenue was up 21%, revenue from PCT sales was up 34%, and operating loss plummeted a full 24%. The company also saw stark increases in grant revenue and the sale of PCT-based consumables. Conrad F Mir, CFO of Pressure Biosciences, also pointed out that the postings compared favorable to Q4 of 2012, showing large gains in both total revenue and PCT products revenue.

May 16th Respected scientific journal Analytical Chemistry published a study by a leading Harvard Medical School researcher that showed the use of PBIO’s “PCT” technology significantly enhanced researchers’ ability to extract lipids, molecules often associated with a number of diseases, from fecal matter. According to the study, this “opens the door to the use of fecal lipid profiling for both scientific and clinical applications,” indicating to the scientific community that PCT is a viable gateway to breakthroughs in the treatment of serious diseases.

Pressure Biosciences is a seasoned company making waves in the life science industry by developing a unique path to financial gains and refusing to rest on the laurels of its established intellectual property. Instead, by pursuing the betterment of its core foundations and resources, with such advances as the implementation of the new “HT” method into its tried and true PCT technology, PBIO continues to reinvent itself while remaining a solid investment.

Always read our full disclaimer/disclosure pertaining to this article
http://tomorrowsbluechips.com/disclaimer/

Seraphim Strategies
1447 S Federal
Boynton Beach FL 33435
727.489.9939
Lou Levenstein

www.tomorrowsbluechips.com

Forward-Looking Statements
Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements.These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Seraphim Strategies
Seraphim Strategies
727-489-9939
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.